申请人:Hancox Timothy Colin
公开号:US20100190769A1
公开(公告)日:2010-07-29
Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R
1
and R
2
form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R is H or C
1
-C
6
alkyl; and R is an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
式(I)的噻唑嘧啶化合物:其中W代表噻唑环;R1和R2与它们所附着的N原子一起形成下式(IIa)的基团:其中A是一个环系统;m为0、1或2;R为H或C1-C6烷基;R为未取代或取代的吲哚基团;以及其药学上可接受的盐是PI3K的抑制剂,并且选择性地作用于p110δ同工型,这是一种Ia类PD激酶,而不是其他Ia类和Ib类激酶。这些化合物可用于治疗由PI3激酶导致的异常细胞生长、功能或行为引起的疾病和障碍,例如癌症、免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌功能障碍和神经系统障碍。